1. Aryldiketo Acids Have Antibacterial Activity Against MDRStaphylococcus aureusStrains: Structural Insights Based on Similarity and Molecular Interaction Fields
- Author
-
Ivan O. Juranić, Željko S. Žižak, Mire Zloh, Branko J. Drakulić, Simon Gibbons, Michael Stavri, and Tatjana Ž. Verbić
- Subjects
Models, Molecular ,Staphylococcus aureus ,medicine.drug_class ,Tetracycline ,Antibiotics ,Integrase inhibitor ,biological activity ,MRSA ,Drug resistance ,Biology ,medicine.disease_cause ,Hydrocarbons, Aromatic ,01 natural sciences ,Biochemistry ,antibiotics ,Microbiology ,aryldiketo acids ,Structure-Activity Relationship ,Drug Resistance, Multiple, Bacterial ,Drug Discovery ,medicine ,General Pharmacology, Toxicology and Pharmaceutics ,Pathogen ,molecular similarity ,Pharmacology ,Molecular Structure ,010405 organic chemistry ,Elvitegravir ,Organic Chemistry ,molecular interaction fields ,Ketones ,Anti-Bacterial Agents ,3. Good health ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Molecular Medicine ,Antibacterial activity ,Acids ,medicine.drug - Abstract
Staphylococcus aureus is a major communityand hospitalacquired pathogen. Reports of resistance to antibiotics, including the fluoroquinolone class, have placed a greater emphasis on the development of new drugs for the treatment of both methicillin(MRSA) and multidrug-resistant (MDR) S. aureus strains. Recently, mixed quinolonediketo acid derivatives, which are based on the scaffold of fluoroquinolone antibiotics, were shown to exert significant anti-HIV-1 potency. The g-diketo moiety is also found in tetracycline, and is therefore potentially important for antibacterial activity. GS-9137 (elvitegravir, CAS 697761-98-1), a 4-quinolone-3-carboxylic acidbased HIV-1 integrase inhibitor is presently in phase III clinical trials. The similarity between these two scaffolds (Figure 1)
- Published
- 2009